|
|
Blood, 1 January 2007, Vol. 109, No. 1, pp. 365-373.
Prepublished online as a Blood First Edition Paper on August 24, 2006; DOI 10.1182/blood-2006-04-014100.
Previous Article | Next Article 
Submitted April 7, 2006
Accepted August 12, 2006
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from anti-leukemic and anti-tumor donor T-cell lines
Thomas C. Wehler, Marion Nonn, Britta Brandt, Cedrik M. Britten, Mark Grone, Mariya Todorova, Irina Link, Shamsul A Khan, Ralf G Meyer, Christoph Huber, Udo F Hartwig, and Wolfgang Herr*
Dept. of Hematology & Oncology, University School of Medicine, Johannes Gutenberg-University Mainz
* Corresponding author; email: w.herr{at}3-med.klinik.uni-mainz.de.
In HLA-incompatible hematopoietic stem-cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA-class-I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch transfected K562 cells or recipient-derived fibroblasts. Selective allo-depletion (SAD) was subsequently performed by a newly developed immunomagnetic depletion approach targeting the tumor necrosis factor receptor molecule CD137 (4-1BB). Compared to other activation-induced antigens, CD137 showed a superior performance based on a consistently low baseline expression and a rapid up-regulation following alloantigen stimulation. In 15 different SAD experiments, the frequency of alloreactive CD8 T cells was reduced to a median of 9.5% compared to undepleted control populations. The allo-depleted T-cell subsets maintained significant anti-tumor and anti-viral CD8 responses. In vitro expansion of tumor-reactive T cells followed by CD137-mediated SAD might enhance the anti-tumor efficacy of T-cell allografts with lower risk of inducing GVHD.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation
- Persis J. Amrolia, Giada Muccioli-Casadei, Helen Huls, Stuart Adams, April Durett, Adrian Gee, Eric Yvon, Heidi Weiss, Mark Cobbold, H. Bobby Gaspar, Cliona Rooney, Ingrid Kuehnle, Victor Ghetie, John Schindler, Robert Krance, Helen E. Heslop, Paul Veys, Ellen Vitetta, and Malcolm K. Brenner
Blood 2006 108: 1797-1808.
[Abstract]
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
S. Mielke, R. Nunes, K. Rezvani, V. S. Fellowes, A. Venne, S. R. Solomon, Y. Fan, E. Gostick, D. A. Price, C. Scotto, et al.
A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique
Blood,
April 15, 2008;
111(8):
4392 - 4402.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mielke, K. Rezvani, B. N. Savani, R. Nunes, A. S. M. Yong, J. Schindler, R. Kurlander, V. Ghetie, E. J. Read, S. R. Solomon, et al.
Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease
Blood,
September 1, 2007;
110(5):
1689 - 1697.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Wolfl, J. Kuball, W. Y. Ho, H. Nguyen, T. J. Manley, M. Bleakley, and P. D. Greenberg
Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities
Blood,
July 1, 2007;
110(1):
201 - 210.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |